Corcept Therapeutics Files Proxy Statement Supplement

TL;DR

Corcept filed more proxy docs for shareholder meeting, no fee.

AI Summary

Corcept Therapeutics Inc. filed a Definitive Additional Materials proxy statement on April 18, 2024, related to its Annual Meeting of Stockholders. The filing is a supplement to the original proxy statement and does not require a fee. Corcept Therapeutics is a pharmaceutical preparations company based in Menlo Park, California.

Why It Matters

This filing provides additional information to shareholders regarding the upcoming Annual Meeting, ensuring they have all necessary details for voting on company matters.

Risk Assessment

Risk Level: low — This is a routine administrative filing related to a shareholder meeting, not indicating any immediate financial or operational risks.

Key Players & Entities

• Corcept Therapeutics Inc. (company) — Registrant
• 149 Commonwealth Drive (location) — Business and Mail Address
• Menlo Park, California (location) — Business and Mail Address
• 20240418 (date) — Filing Date

FAQ

Filing Documents

• d826835ddefa14a.htm (DEFA14A) — 13KB
• 0001193125-24-100927.txt ( ) — 14KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 CORCEPT THERAPEUTICS INCORPORATED (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park, California 94025 Supplement to Proxy Statement for the Annual Meeting of Stockholders To Be Held on May 17, 2024 This proxy statement supplement, dated April 18, 2024 (the Supplement), supplements the definitive proxy statement on Schedule 14A of Corcept Therapeutics Incorporated (the Company), dated April 10, 2024 (the Proxy Statement), for the Companys Annual Meeting of Stockholders to be held on May 17, 2024 (the Annual Meeting). The Company is providing this Supplement solely to correct the number of shares of common stock outstanding as of April 5, 2024 (the Record Date). The number of shares of common stock outstanding as of the Record Date was incorrectly stated in the Proxy Statement as 103,837,166 shares of common stock. The correct number of shares of common stock outstanding as of the Record Date is 104,082,845, all of which are entitled to vote at the Annual Meeting. For the purposes of the sections Shares Outstanding and Quorum, Security Ownership of Certain Beneficial Owners and Management, and Proposal No. 4 Approval of the Corcept Therapeutics Incorporated 2024 Incentive Award Plan Incentive Award Plan Information in the Proxy Statement, the number of shares of common stock outstanding as of the Record Date is restated as 104,082,845 shares of common stock. The shares of common stock beneficially owned by the Companys directors, executive officers and five percent stockholders under Security Ownership of Certain Beneficial for there to be a quorum at the meeting. Except as specifically supplemented by the information contained in this Supplement, all information set forth in the Proxy Statement continues to apply and should be considered in voting your shares. Voting Matters Please note that any proxy card that you requested or that we elected to deliver has not changed and may still be used to vote your shares in connection with the Annual Meeting. If you have already submitted your vote, you do not need to take any further action. Information on how to vote your shares and how to change your vote or revoke your proxy is contained in the Proxy Statement. The Company urges stockholders to vote their shares prior to the Annual Meeting by using one of the methods described in the Proxy Statement. By Order of the Board of Directors, /s/ Charles Robb Charles Robb Chief Business Officer and Secretary Menlo Park, California April 18, 2024

View Full Filing

View this DEFA14A filing on SEC EDGAR